Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Ampronix

Codeine Following Tonsillectomy Contraindicated in Children

By HospiMedica International staff writers
Posted on 06 Mar 2013
Print article
A new safety review shows that products that contain codeine should not be used for pain relief following tonsillectomy or adenoidectomy in children, due to a possible risk of serious adverse events.

The warning, issued by the US Food and Drug Administration (FDA; Silver Spring, MD, USA), is based on reports of three deaths and one life-threatening case of respiratory depression published in the medical literature following the use of codeine in children with obstructive sleep apnea (OSA) who underwent tonsillectomy or adenoidectomy. The children were determined to be ultra-rapid metabolizers, genetically susceptible to converting normal doses of codeine into dangerous levels of morphine in the body.

Following the reports, a review of the FDA's Adverse Event Reporting System from 1969 to May 1, 2012, and a physician survey conducted by the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS; Alexandria, VA, USA) uncovered a total of 12 deaths and three overdoses associated with codeine use in patients ranging in age from 21 months to 9 years. Eight of the cases involved codeine use after adenotonsillectomy, and three involved a respiratory tract infection. The codeine doses were appropriate in most cases.

“Since these children already had underlying breathing problems, they may have been particularly sensitive to the breathing difficulties that can result when codeine is converted in the body to high levels of morphine,” concluded the FDA advisory. “However, [the new] contraindication applies to all children undergoing tonsillectomy and/or adenoidectomy because it is not easy to determine which children might be ultra-rapid metabolizers of codeine.”

A boxed warning regarding the contraindication will be added to the labels of all codeine-containing products in the United States. The contraindication to codeine use does not apply to other types of pain management in children, although the FDA recommends that codeine should only be used if the benefits are anticipated to outweigh the risks.

Codeine (3-methylmorphine), a natural isomer of methylated morphine, is an opiate used for its analgesic, antitussive, antidiarrheal, antihypertensive, antianxiety, sedative, and hypnotic properties. It is used to suppress premature labor contractions, myocardial infarction (MI), cough suppression, as well as many other uses. Common adverse effects associated with the use of codeine include drowsiness, constipation, euphoria, itching, nausea, vomiting, and others. Rare adverse effects include anaphylaxis, seizure, and respiratory depression.

Related Links:

US Food and Drug Administration
American Academy of Otolaryngology-Head and Neck Surgery



Print article
Radcal
Fluke Biomedical

Channels

Women's Health

view channel
Image: The vaginal probe device, designed for cervical cancer screening (Photo courtesy of Biop Medical).

Optical Scanner Advances Cervical Cancer Screening

A new technology optimizes the cervical cancer (CC) screening process into a single, three-minute painless optical scan. The Biop device is a probe inserted into the vaginal canal that optically identifies... Read more

Business

view channel

Otsuka and IBM Partner in Digital Health Venture

IBM (Armonk, NY, USA) and Otsuka Pharma (Tokyo, Japan) have formed a joint venture to market software that will integrate and analyze psychiatric patient data in Japan. The joint venture will be named Otsuka Digital Health, with the pharma company taking an 85% stake and IBM Japan holding the remaining 15%.... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.